Studies have shown significant variation in physician
knowledge of glucocorticoid-induced osteoporosis
with these agents, and many physicians do not consider
addressing the fracture risk as complication of
glucocorticoid-induced bone loss. In many patients,
bone loss can occur quickly with oral glucocorticoid
therapy; but even inhaled glucocorticoids, with
their lower systemic distribution, may cause loss
of bone mineral density. Topics
covered in this program
- The effects of glucocorticoids on
bone remodeling.
- Evaluation of patients at risk for
glucocorticoid-induced osteoporosis and secondary
osteoporosis.
- Management options to minimize bone
loss.
The American Medical Association is accredited by
the Accreditation
Council for Continuing Medical Education (ACCME)
to provide continuing medical education for physicians.
The American Medical Association designates this
module for a maximum of 1.5 AMA PRA Category 1
Credits™. Physicians should only claim
credit commensurate with the extent of their participation
in the activity.
Nonphysicians may receive a certificate of participation
for completing this activity.
The development of this CME web module was supported
in part through an independent education grant from
the Alliance for Better Bone Health and produced in
accordance with the AMA Standards for Industry-Supported
Multimedia Continuing Medical Education and Other
Communications.
|
